Experimental immune cell therapy for relapsed follicular lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests an experimental treatment called TC011, which uses your own immune cells to fight your lymphoma. It is designed for people whose follicular lymphoma has not responded to or has returned after at least two prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years of age or older.
- You have follicular lymphoma (grade 1, 2, or 3a) that has come back or not responded after at least two prior treatments, including rituximab.
- You have at least one tumor that can be measured (at least 1.5 cm).
- Your overall health is good enough for daily activities (not bedridden).
- You are willing to use effective birth control for 6 months after the treatment.
- You have not had certain prior treatments like CAR T-cell therapy or a donor stem cell transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (called AbTCR T-cells) that targets two markers (CD19 and CD22) found on your lymphoma cells. The goal is to see if these modified cells can safely and effectively destroy your cancer when other treatments haven't worked.
This study tests a new drug combination (using two targeted medicines and an immunotherapy drug) versus a standard chemotherapy combination for people with untreated follicular lymphoma. The goal is to see if the new combo works better with fewer side effects.
This trial tests whether the experimental drug TC011 can help adults with a type of B-cell lymphoma that has come back or stopped responding after at least two rounds of chemotherapy. The study checks for safety and whether the treatment can shrink tumors.
This trial tests a new kind of immune cell therapy for people with certain types of lymphoma that have come back or not responded to previous treatments. The cells are made from your own blood and are designed to find and attack the cancer cells.
This trial tests a new type of CAR T-cell therapy that may help people with follicular lymphoma that has come back or not responded to earlier treatments. The therapy uses your own immune cells, modified to recognize and attack the cancer cells.
This study tests a new type of immunotherapy called CAR-T cells (designed cells that fight lymphoma) given after you've received standard chemotherapy for follicular lymphoma. The goal is to help prevent the cancer from coming back or growing, especially if your cancer didn't fully disappear or you have high-risk features.
Hear when a new Follicular Lymphoma (FL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.